Oncology Landing 2015 Content

Publication
Article

NOVEMBER 2015

Volume 29 • Number 11

featured article

Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma

Benjamin A. Weinberg, MD, Cinthya S. Yabar, MD, Jonathan R. Brody, PhD, and Michael J. Pishvaian, MD, PhD

This article reviews the current treatment paradigms for metastatic disease, focusing on ways to ameliorate symptoms and lengthen survival. We then summarize recent advances in our understanding of the molecular and cellular aspects of pancreatic cancer.

Read article

Related Links

About Us

Archives

Supplements

Subscribe

Advertising

Guide to Authors

Reprints / Permissions

Editors / Publishers

Contact Us

October 2015 Issue

Oncology Digital Edition

view Past Digital Editions

Editors-in-Chief:

Julie M. Vose, MD

Nancy E. Davidson, MD

Nora Janjan, MD, MPSA, MBA

William C. Wood, MD

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content
The FDA originally approved this thiotepa formulation as a therapy for patients with breast or ovarian cancers in June 2024.

FDA Approves Multi-Dose Thiotepa Vial for Breast and Ovarian Cancers

Russ Conroy
April 30th 2025
Article

The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

The CHMP Recommends Acalabrutinib Combos For Approval in Untreated CLL

The CHMP Recommends Acalabrutinib Combos For Approval in Untreated CLL

Tim Cortese
April 30th 2025
Article

Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI

81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI

Joseph Peterson;Bradley Figer;Poornima Saha;Frederick Howard;Erica Stringer-Reasor
April 29th 2025
Article
The safety profile of capivasertib in the phase 3 CAPItello-280 trial (NCT05348577) was comparable with prior reports of the agent.

Investigators Discontinue Trial Assessing Capivasertib in Metastatic CRPC

Russ Conroy
April 29th 2025
Article

A recommendation from an independent data monitoring committee prompted the discontinuation of the phase 3 CAPItello-280 trial.